Table 1 Baseline characteristics and prior lines of therapy
From: ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial
N = 37 | |
|---|---|
Age, median (range), years | 60 (41‒81) |
Female, n (%) | 36 (97.3) |
Postmenopausal | 35 (94.6) |
Race, n (%) | |
White | 29 (78.4) |
Black | 5 (13.5) |
Asian | 0 |
Not reported | 2 (5.4) |
Multiple | 1 (2.7) |
Baseline ECOG PS, n (%) | |
0 | 15 (40.5) |
1 | 22 (59.5) |
Measurable disease at baseline, n (%) | 30 (81.1) |
Visceral lesions (liver, lung, spleen) at baseline, n (%) | 26 (70.3) |
Bone lesions only at baseline, n (%) | 7 (18.9) |
Prior lines of therapy | |
Systemic therapy in any setting, median (range) | 5 (1‒10) |
Systemic therapy in advanced/metastatic setting, median (range) | 3 (1‒8) |
Prior CDK4/6 inhibitors, n (%) | 37 (100) |
Prior palbociclib | 29 (78.4) |
Prior ribociclib | 5 (13.5) |
Prior abemaciclib | 9 (24.3) |
Prior CDK4/6 inhibitors <12 months | 14 (37.8) |
Prior ET in advanced/metastatic settings, median (range) | 2 (1‒7) |
Prior ET in advanced/metastatic settings, n (%) | 37 (100) |
Prior fulvestrant | 30 (81.1) |
Prior novel SERD/SERCAa | 8 (21.6) |
Prior chimeric ER degrader | 4 (10.8) |
Prior aromatase inhibitors | 26 (70.3) |
Prior chemotherapy, n (%) | 31 (83.8) |
Prior chemotherapy in metastatic setting, n (%) | 20 (54.1) |
Prior to other targeted therapies (mTOR and PIK), n (%) | 11 (29.7) |
ESR1 mutant, VAF > 1%, n (%) | 12 (32.4) |
